Mode
Text Size
Log in / Sign up
N/A N=43 Randomized Single-blind Treatment

Effects of Aerobic Exercise in Parkinson's Disease

Parkinson Disease

Enrolled (actual)
43
Serious AEs
0.0%
Results posted
Sep 2015
Primary outcome: Primary: Change in Aerobic Fitness — 1.56 ml/min/kg — p=<0.001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Continuous training (Behavioral); Interval training (Behavioral)
Age
Adult, Older Adult · 50+ yrs
Sex
All
Sponsor
US Department of Veterans Affairs
Primary completion
May 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Aerobic Fitness
1.56 <0.001 sig
SECONDARY
Change in 7 Meter Walk Time
-0.85 <0.001 sig
SECONDARY
Change in the UPDRS Section I Score
-0.5 0.029 sig
SECONDARY
Change in UPDRS Section II Score
-0.4 0.271
SECONDARY
Change in the UPDRS Section III Score
-3.4 0.002 sig
SECONDARY
Change in the Total UPDRS Score
-3.8 0.003 sig
SECONDARY
Change in the MOCA Score
0.4 =0.146
SECONDARY
Change in Percent Increase Score (PIS) on Eriksen's Flanker Task
-2.41 0.037 sig

Summary

Motivated by reported improvements in aerobic fitness and executive functions after a 6-month aerobic walking intervention in normal sedentary elderly, we conducted a Phase I/II study to investigate effects of aerobic exercise on motor function, cognition, and quality of life in mild-moderate patients with Parkinson's disease (PD). To identify the best method to deliver fitness training, we also aimed to compare safety, tolerability, and fitness benefits between different training methods (continuous/moderate intensity vs. interval/alternating between low and vigorous intensity) and exercise settings (individual vs. group). Interval training reportedly facilitates higher fitness gains than continuous training. Group training may promote success through social interaction, whereas individual training offers greater flexibility. Details of the study can be found in the publication below: Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting. Uc EY, Doerschug KC, Magnotta V, Dawson JD, Thomsen TR, Kline JN, Rizzo M, Newman SR, Mehta S, Grabowski TJ, Bruss J, Blanchette DR, Anderson SW, Voss MW, Kramer AF, Darling WG. Neurology. 2014 Jul 29;83(5):413-25. doi: 10.1212/WNL.0000000000000644. Epub 2014 Jul 2. PMID: 24991037

Eligibility Criteria

Inclusion Criteria

  • Veteran or non-veteran;
  • Presence of all 3 cardinal features of Parkinson's disease (resting tremor, bradykinesia, and rigidity), which have to be asymmetrical;
  • Hoehn and Yahr Scale stage I-III;
  • Men or women aged 50-80 capable of performing the planned exercise programs;
  • Intention to remain in the local area over the study period;
  • Stable dopaminergic treatment regimen for at least 4 weeks prior to baseline without any clinical need for medication adjustment at the time of screening

Exclusion Criteria

  • Secondary parkinsonism;
  • Parkinson-plus syndromes;
  • MMSE score 1 month vacation during the study period;
  • Contraindications to MRI or claustrophobia requiring sedation
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00784563). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search